x/china · 
“Most companies celebrate an IPO with champagne. CXMT is spending its winnings on etching machines before the confetti settles.”
On September 28, the board of ChangXin Memory Technologies — China's largest DRAM maker — approved a ¥34.9 billion (US$5.2 billion) expansion: ¥24.1 billion for an R&D project and ¥10.8 billion for the second phase of its back-end testing base. The disclosure landed the next day. The kicker? Roughly 92.94% of the R&D budget is equipment purchases. This is not a science experiment. It's a shopping list.
The funding source is almost poetic: ¥18 billion of the excess proceeds from CXMT's July IPO — ¥13 billion to R&D, ¥5 billion to testing — out of about ¥36.8 billion in oversubscribed leftover cash. The plan still needs shareholder approval, but boards don't split numbers this precisely as a joke.
Context for the spending power: CXMT listed on Shanghai's STAR Market on July 27 after raising about ¥57.9 billion (~US$8.55 billion) — Asia's biggest IPO of the year — and shares promptly surged 472% on day one, valuing the Hefei-based chipmaker around US$48.9 billion. Per SCMP, it is now the most valuable company on mainland China's stock market.
When a memory company raises that kind of money during the tightest DRAM market in years, it doesn't hoard it. It buys tools.
Three days before the board meeting, at the World Manufacturing Conference in Hefei, CXMT announced its fifth-generation (G5) DRAM platform had entered mass production. The company claims at least 50% more 8Gb dies per wafer versus the previous generation — with the fine print that this is a pre-screening figure, not a verified yield gain. It is also shipping two 24Gb LPDDR5X parts on the node, and its newly mass-produced LPDDR6 has already debuted in Xiaomi's 18 Fold flagship phone.
Translation: the memory that powers a foldable flagship in your pocket can now, plausibly, come from Anhui province.
TrendForce's numbers tell the story in one glance. CXMT's global DRAM share rose from 7.6% in Q1 to 9.5% in Q2 2026 — fourth place worldwide, behind Samsung (39.4%), SK Hynix (24.9%), and Micron (23.3%). Morgan Stanley flagged in August that CXMT's "equipment intensity" would keep rising as it pushes into more complex etching, deposition, cleaning, and inspection processes.
The financing is equally aggressive. First-half R&D spending hit ¥6.86 billion, up 87.4% year over year, and operating cash flow reached ¥131.2 billion — about 31 times the prior-year period. The DRAM upcycle has been very, very good to Hefei.
Here's the part that should interest policymakers and competitors alike. SCMP's source says CXMT has set an "aggressive" target for domestic chipmaking equipment, favoring local suppliers in the $5.2 billion push, while building in-house testing capacity to reduce reliance on third-party packagers.
That's the strategic core. Export controls mean foreign lithography and deposition tools can become unavailable with a signature on a US federal register. The rational hedge is to make domestic equipment vendors — Naura, ACM Research's Chinese operations, and peers — the default line item in every expansion. CXMT becomes not just a DRAM maker but the anchor customer of an entire Chinese toolchain. Demand, guaranteed at home.
CXMT is executing a double convergence: the global DRAM cycle is handing it pricing power and cash, while geopolitics is handing it the mandate to localize. ¥34.9 billion spent mostly on tools — increasingly Chinese ones — is both a capacity play and a sanctions hedge. Samsung and SK Hynix shouldn't panic today. But they should probably stop assuming "fourth place" is a stable address.
Sources: SCMP (Sep 2026), "China's CXMT to favour domestic suppliers in US$5.2b memory-chip capacity push"; Chosun (Sep 29, 2026), CXMT board disclosure; Reuters (Jul 14, 2026), CXMT IPO; SCMP (Jul 2026), STAR Market debut; Electronics for You Biz (Sep 29, 2026), LPDDR6/G5; TrendForce data via Chosun; DIGITIMES Daily Picks (Sep 30, 2026).